Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
J Biol Chem. 2011 May 27;286(21):18452-64. doi: 10.1074/jbc.M111.229872. Epub 2011 Mar 25.
Scavenger receptor class B, type I (SR-BI), a CD36 superfamily member, is an oligomeric high density lipoprotein (HDL) receptor that mediates negatively cooperative HDL binding and selective lipid uptake. We identified in the N-terminal transmembrane (N-TM) domain of SR-BI a conserved glycine dimerization motif, G(15)X(2)G(18)X(3)AX(2)G(25), of which the submotif G(18)X(3)AX(2)G(25) significantly contributes to homodimerization and lipid uptake activity. SR-BI variants were generated by mutations (single or multiple Gly → Leu substitutions) or by replacing the N-TM domain with those from other CD36 superfamily members containing (croquemort) or lacking (lysosomal integral membrane protein (LIMP) II) this glycine motif (chimeras). None of the SR-BI variants exhibited altered surface expression (based on antibody binding) or HDL binding. However, the G15L/G18L/G25L triple mutant exhibited reductions in cell surface homo-oligomerization (>10-fold) and the rate of selective lipid uptake (∼ 2-fold). Gly(18) and Gly(25) were necessary for normal lipid uptake activity of SR-BI and the SR-BI/croquemort chimera. The lipid uptake activity of the glycine motif-deficient SR-BI/LIMP II chimera was low but could be increased by introducing glycines at positions 18 and 25. The rate of lipid uptake mediated by SR-BI/LIMP II chimeras was proportional to the extent of receptor oligomerization. Thus, the glycine dimerization motif G(18)X(3)AX(2)G(25) in the N-TM domain of SR-BI contributes substantially to the homo-oligomerization and lipid transport activity of SR-BI but does not influence the negative cooperativity of HDL binding. Oligomerization-independent binding cooperativity suggests that classic allostery is not involved and that the negative cooperativity is probably the consequence of a "lattice effect" (interligand steric interference accompanying binding to adjacent receptors).
清道夫受体 B 类,I 型(SR-BI),是 CD36 超家族成员,是一种寡聚高密度脂蛋白(HDL)受体,介导负协同性 HDL 结合和选择性脂质摄取。我们在 SR-BI 的 N 端跨膜(N-TM)域中鉴定出一个保守的甘氨酸二聚化基序,G(15)X(2)G(18)X(3)AX(2)G(25),其中亚基序 G(18)X(3)AX(2)G(25)对同源二聚化和脂质摄取活性有重要贡献。通过突变(单个或多个甘氨酸→亮氨酸取代)或用包含(croquemort)或缺乏(溶酶体整合膜蛋白(LIMP)II)此甘氨酸基序的其他 CD36 超家族成员的 N-TM 域替换,生成了 SR-BI 变体(嵌合体)。没有一种 SR-BI 变体表现出改变的表面表达(基于抗体结合)或 HDL 结合。然而,G15L/G18L/G25L 三突变体显示细胞表面同源寡聚化减少(>10 倍)和选择性脂质摄取率降低(~2 倍)。甘氨酸 18 和 25 对 SR-BI 的正常脂质摄取活性和 SR-BI/croquemort 嵌合体是必要的。缺乏甘氨酸基序的 SR-BI/LIMP II 嵌合体的脂质摄取活性较低,但在位置 18 和 25 引入甘氨酸可增加其活性。由 SR-BI/LIMP II 嵌合体介导的脂质摄取速率与受体寡聚化的程度成正比。因此,SR-BI 的 N-TM 域中的甘氨酸二聚化基序 G(18)X(3)AX(2)G(25)对 SR-BI 的同源寡聚化和脂质转运活性有很大贡献,但不影响 HDL 结合的负协同性。不依赖于寡聚化的结合协同性表明经典变构作用不参与,负协同性可能是“晶格效应”(伴随结合到相邻受体的配体间空间干扰)的结果。